Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1088609

Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study


Majić, Ana; Petrić Miše, Branka; Matković, Višnja; Belac Lovasić, Ingrid; Katić, Kristina; Canjko, Ivana; Frobe, Ana; Bajić, Žarko; Vrdoljak, Eduard
Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study // Journal of Oncology, 2020 (2020), 1-6 doi:10.1155/2020/6423936 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1088609 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study

Autori
Majić, Ana ; Petrić Miše, Branka ; Matković, Višnja ; Belac Lovasić, Ingrid ; Katić, Kristina ; Canjko, Ivana ; Frobe, Ana ; Bajić, Žarko ; Vrdoljak, Eduard

Izvornik
Journal of Oncology (1687-8450) 2020 (2020); 1-6

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
olaparib, BRCA mutated ovarian carcinoma, Retrospective study
(olaparib, BRCA mutated ovarian carcinoma, retrospective study)

Sažetak
Our objective was to assess the safety and efficacy of olaparib in maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma after the partial or complete response to the second or further lines platinum- based chemotherapy in a real-world setting. We performed a multicenter, real-world observational population-based cohort study on the whole population of Croatian patients initiated to olaparib maintenance therapy between 2016 and 2020. (e primary endpoints were progression-free survival and the discontinuation of treatment because of adverse events. We enrolled the total population of 69 patients with the median (interquartile range ; IQR) age of 53 (48– 59), 56 (81%) of them with BRCA1 mutation. (e median (IQR) follow-up was 16 (9–25) months. Treatment had to be discontinued because of toxicity in 2 (3%) and temporarily interrupted in 14 (20%), while dose was reduced because of toxicity in 18 (26%) of patients. Toxicity of any grade was observed in 61 (88%) patients and toxicity of grade 3 or 4 in 12 (17%). Median progression-free survival was 21 (95% CI 16-not calculable) months from the introduction of olaparib, and the median overall survival was not reached. Our study confirmed efficacy and safety of olaparib as the maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma. We observed the real- world efficacy and safety comparable to those observed in the randomized controlled trials. We found the interesting observation of better efficacy of 300mg tablets, compared to 400mg capsules, an issue that should be addressed on much larger real-world populations.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Majić, Ana; Petrić Miše, Branka; Matković, Višnja; Belac Lovasić, Ingrid; Katić, Kristina; Canjko, Ivana; Frobe, Ana; Bajić, Žarko; Vrdoljak, Eduard
Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study // Journal of Oncology, 2020 (2020), 1-6 doi:10.1155/2020/6423936 (međunarodna recenzija, članak, znanstveni)
Majić, A., Petrić Miše, B., Matković, V., Belac Lovasić, I., Katić, K., Canjko, I., Frobe, A., Bajić, Ž. & Vrdoljak, E. (2020) Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology, 2020, 1-6 doi:10.1155/2020/6423936.
@article{article, author = {Maji\'{c}, Ana and Petri\'{c} Mi\v{s}e, Branka and Matkovi\'{c}, Vi\v{s}nja and Belac Lovasi\'{c}, Ingrid and Kati\'{c}, Kristina and Canjko, Ivana and Frobe, Ana and Baji\'{c}, \v{Z}arko and Vrdoljak, Eduard}, year = {2020}, pages = {1-6}, DOI = {10.1155/2020/6423936}, keywords = {olaparib, BRCA mutated ovarian carcinoma, Retrospective study}, journal = {Journal of Oncology}, doi = {10.1155/2020/6423936}, volume = {2020}, issn = {1687-8450}, title = {Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study}, keyword = {olaparib, BRCA mutated ovarian carcinoma, Retrospective study} }
@article{article, author = {Maji\'{c}, Ana and Petri\'{c} Mi\v{s}e, Branka and Matkovi\'{c}, Vi\v{s}nja and Belac Lovasi\'{c}, Ingrid and Kati\'{c}, Kristina and Canjko, Ivana and Frobe, Ana and Baji\'{c}, \v{Z}arko and Vrdoljak, Eduard}, year = {2020}, pages = {1-6}, DOI = {10.1155/2020/6423936}, keywords = {olaparib, BRCA mutated ovarian carcinoma, retrospective study}, journal = {Journal of Oncology}, doi = {10.1155/2020/6423936}, volume = {2020}, issn = {1687-8450}, title = {Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study}, keyword = {olaparib, BRCA mutated ovarian carcinoma, retrospective study} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font